Oral health behaviors in medical patients with diabetes mellitus.

J Dent Hyg

Department of Family and Community Medicine, The Bowman Gray School of Medicine of Wake Forest University Medical Center, Winston-Salem, North Carolina, USA.

Published: July 1996

Purpose: Periodontal disease is common among patients with noninsulin dependent diabetes mellitus (NIDDM) and insulin dependent diabetes mellitus (IDDM) and interferes with diabetic control. However, no study has examined predictors of oral health behavior among patients with diabetes in a medical setting. This study describes self-reported oral hygiene among primary care patients with IDDM and NIDDM, evaluating age, race, gender, psychosocial stress, family dysfunction, and other health predictors of preventive oral behaviors.

Methods: A written survey of oral health behaviors, psychological stress, and family function was conducted among 390 out of 473 possible primary care dentate patients with diabetes (IDDM=81; NIDDM=309). Fasting blood sugar and hemoglobin A1C also were obtained. Data were collected between January 1989 and June 1991, and analyzed using Mantel-Haenszel's chi-square and logistic regression.

Results: Patients with IDDM with severe family dysfunction were less likely to brush, floss, or visit a dentist regularly than those with better reported family function. Whites with NIDDM were more likely to practice these oral health behaviors than were blacks. Female gender correlated with flossing in the group of patients with IDDM, and with brushing in both groups. Patients with NIDDM who exercised were also more likely to visit the dentist annually. Age was positively associated with a history of periodontal disease in the group with IDDM.

Conclusions: These data document for the first time the relationship between family dysfunction and oral health practices of patients with IDDM, and corroborate the known associations among white race, female gender, and oral hygiene. This information could be used to coordinate diabetic oral health promotion between primary care physicians and oral health professionals.

Download full-text PDF

Source

Publication Analysis

Top Keywords

oral health
28
patients iddm
16
health behaviors
12
patients diabetes
12
diabetes mellitus
12
primary care
12
family dysfunction
12
oral
10
patients
9
periodontal disease
8

Similar Publications

Background: Although investment in biomedical and pharmaceutical research has increased significantly over the past two decades, there are no oral disease-modifying treatments for Alzheimer's disease (AD).

Method: We performed comprehensive human genetic and multi-omics data analyses to test likely causal relationship between EPHX2 (encoding soluble epoxide hydrolase [sEH]) and risk of AD. Next, we tested the effect of the oral administration of EC5026 (a first-in-class, picomolar sEH inhibitor) in a transgenic mouse model of AD-5xFAD and mechanistic pathways of EC5026 in patient induced Pluripotent Stem Cells (iPSC) derived neurons.

View Article and Find Full Text PDF

Background: Epidemiological studies report an elevated risk of neurodegenerative disorders, particularly Parkinson's disease (PD), in patients with type 2 diabetes mellitus (T2DM) that is mitigated in those prescribed incretin mimetics or dipeptidyl peptidase 4 inhibitors (DPP-4Is). Incretin mimetic repurposing appears promising in human PD and Alzheimer's disease (AD) clinical trials. DPP-4Is are yet to be evaluated in PD or AD human studies.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Merry Life Biomedical Company, Ltd., Tainan City, Taiwan, Taiwan.

Background: Alzheimer's disease (AD) is complex in pathogenesis and related to aging biology, especially in late-onset AD. We identified a novel synthetic curcumin analog TML-6 through the platform of 6 biomarkers of anti-aging, anti-inflammation, and anti-Aβ as the potential AD drug candidate. TML-6 exhibits multi-target effects on AD pathogenesis, including the activation of NrF-2, the regulation of autophagic machinery through mTOR, the inhibition of APP synthesis and reduction of Aβ, the upregulation of ApoE, and the inhibition of microglial activation.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Vigil Neuroscience, Inc, Watertown, MA, USA.

Background: VG-3927 is a highly potent, selective, brain penetrant, oral small molecule TREM2 agonist that is currently under development for the treatment of Alzheimer's disease (AD). TREM2, a receptor expressed on microglia in the brain is critical to microglial function in health and in disease. Among microglia-associated AD risk genes, partial loss-of-function variants of TREM2 confer 2-3 fold increase in risk for developing AD, motivating efforts to identify pharmacological agonists targeting TREM2 as a therapeutic option.

View Article and Find Full Text PDF

Dementia Care Research and Psychosocial Factors.

Alzheimers Dement

December 2024

Music and Health Science Research Collaboratory, University of Toronto, ON, Canada.

Background: The dual-cyclical relationship between language and cognition, encapsulated in linguistic relativity, underscores the reciprocal influence of thoughts on communication and vice-versa. This study explores the intricate changes in pragmatics, a fundamental aspect of human communication, during the aging process, considering changes in sensory abilities, cognition, and language.

Method: Sixty participants, aged ≥50 years with a minimum of five years of formal education, were included, excluding those with neurological or psychological illnesses.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!